Pyxis Oncology, Inc. (PYXS)

NASDAQ: PYXS · IEX Real-Time Price · USD

12.31

-0.20 (-1.60%)

After-hours:Oct 20, 2021 5:39 PM EDT

12.51

1.02 (8.88%)

At close: Oct 20, 4:00 PM

Market Cap	409.50M
Revenue (ttm)	n/a
Net Income (ttm)	-52.74M
Shares Out	32.73M
EPS (ttm)	-1.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	210,930
Open	11.31
Previous Close	11.49
Day's Range	11.23 - 12.57
52-Week Range	10.89 - 19.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings Date	n/a

About PYXS

Pyxis Oncology is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. We develop our product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. We have developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discov...

IndustryBiotechnology

IPO DateOct 8, 2021

CEOLara Sullivan, M.D.

Employees38

Stock ExchangeNASDAQ

Ticker SymbolPYXS

Full Company Profile